A novel electrochemical immunosensor for ultrasensitive detection of CA125 in ovarian cancer

被引:127
|
作者
Pakchin, Parvin Samadi [1 ,2 ]
Fathi, Marziyeh [2 ]
Ghanbari, Hossein [1 ]
Saber, Reza [1 ,3 ]
Omidi, Yadollah [2 ,4 ]
机构
[1] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Nanotechnol, Tehran, Iran
[2] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Biomed Inst, Tabriz, Iran
[3] Univ Tehran Med Sci, Res Ctr Sci & Technol Med, Tehran, Iran
[4] Tabriz Univ Med Sci, Fac Pharm, Dept Pharmaceut, Tabriz, Iran
来源
关键词
Cancer antigen 125; Chitosan; Electrochemical immunosensor; Polyamidoamine/gold nanoparticles; Ovarian cancer; PROSTATE-SPECIFIC ANTIGEN; IMPEDIMETRIC IMMUNOSENSOR; MODIFIED ELECTRODE; CHITOSAN; NANOPARTICLES; GRAPHENE; BIOMARKER; MARKERS; SURFACE; CELLS;
D O I
10.1016/j.bios.2020.112029
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
In the current study, we report on the design and development of a novel electrochemical immunosensor for the detection of cancer antigen 125 (CA125) oncomarker. Polyamidoamine/gold nanoparticles (PAMAM/AuNPs) were used to increase the conductivity and enhance the number of antibodies (Abs) immobilized on the electrode surface. Three-dimensional reduced graphene oxide-multiwall carbon nanotubes (3DrGO-MWCNTs) were used to modify the glassy carbon electrode to improve the electrode conductivity and specific surface area. Ab and to-luidine blue attached to O-succinyl-chitosan-magnetic nanoparticles (Suc-CS@MNPs) as a tracer. The poor solubility of chitosan (CS) was improved by succinic anhydride using a novel modification method. Under optimum condition, the developed immunosensor exhibited a wide linear range (0.0005-75 U/mL) and an excellent limit of detection around 6 mu U/mL. The reliability of the engineered immunosensor in detecting CA125 was verified by standard addition recovery method, which was further compared to enzyme-linked immunosorbent assay (ELISA). The proposed immunosensor exhibited excellent stability, high selectivity and sensitivity, and good reproducibility. Based on the great performance of the engineered immunosensor, it is proposed as a robust and reliable diagnostic tool for the detection of CA125 in the clinic.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Nadir CA125 concentration as a prognostic indicator in ovarian cancer
    Baron, AT
    Maihle, N
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (06): : 288 - 289
  • [42] Nadir CA125 concentration as a prognostic indicator in ovarian cancer
    Andre T Baron
    Nita Maihle
    Nature Clinical Practice Oncology, 2005, 2 : 288 - 289
  • [43] CA125 response to bevacizumab in recurrent ovarian cancer.
    O'Cearbhaill, R. E.
    Zhou, Q.
    Iasonos, A.
    Diaz, J. P.
    Tew, W. P.
    Hensley, M. L.
    O'Flaherty, C.
    Aghajanian, C.
    Spriggs, D. R.
    Sabbatini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Beyond CA125: the coming of age of ovarian cancer biomarkers
    Sasaroli, Dimitra
    Coukos, George
    Scholler, Nathalie
    BIOMARKERS IN MEDICINE, 2009, 3 (03) : 275 - 288
  • [45] Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer
    Schorge, JO
    Drake, RD
    Lee, H
    Skates, SJ
    Rajanbabu, R
    Miller, DS
    Kim, JH
    Cramer, DW
    Berkowitz, RS
    Mok, SC
    CLINICAL CANCER RESEARCH, 2004, 10 (10) : 3474 - 3478
  • [46] Targeting CA125 transcription for ovarian cancer treatment.
    Yue, Er
    Yang, Guangchao
    Yao, Yuanfei
    Wang, Guangyu
    Zhang, Yanqiao
    Wang, Edward W.
    CANCER RESEARCH, 2021, 81 (13)
  • [47] CA125 based diagnosis and therapy in recurrent ovarian cancer
    Meier, W
    Baumgartner, L
    Stieber, P
    Hasholzner, U
    FatehMoghadam, A
    ANTICANCER RESEARCH, 1997, 17 (4B) : 3019 - 3020
  • [48] Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
    Weiland, Florian
    Martin, Karina
    Oehler, Martin K.
    Hoffmann, Peter
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (08) : 10568 - 10582
  • [49] Serum CA125 level before the development of ovarian cancer
    Kobayashi, H.
    Ooi, H.
    Yamada, Y.
    Sakata, M.
    Kawaguchi, R.
    Kanayama, S.
    Sumimoto, K.
    Terao, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 99 (02) : 95 - 99
  • [50] SERUM CA125 LEVEL BEFORE THE DEVELOPMENT OF OVARIAN CANCER
    Kobayashi, H.
    Ooi, H.
    Yamada, Y.
    Sakata, M.
    Kawaguchi, R.
    Kanayama, S.
    Sumimoto, K.
    Terao, T.
    GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2008, 30 (03): : 91 - 96